Bleichroeder LP 13D/13G Filings for Evoke Pharma, Inc. (EVOK)

Bleichroeder LP 13D and 13G filings for Evoke Pharma, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2024-03-11
6:39 pm
Purchase
2024-02-1313GEvoke Pharma, Inc.
EVOK
Bleichroeder LP70,781
9.990%
70,781increase
(New Position)
Filing